In Vivo Evaluation of White Matter Abnormalities in Children with Duchenne Muscular Dystrophy Using DTI

References

1. 1.↵
   1. Bushby K,
   2. Finkel R,
   3. Birnkrant DJ, et al

   ; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, Part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93 doi:10.1016/S1474-4422(09)70271-6 pmid:19945913

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Pane M,
   2. Lombardo ME,
   3. Alfieri P, et al

   . Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr 2012;161:705–09.e1 doi:10.1016/j.jpeds.2012.03.020 pmid:22560791

   CrossRefPubMedWeb of Science
3. 3.↵
   1. D'Angelo MG,
   2. Lorusso ML,
   3. Civati F, et al

   . Neurocognitive profiles in Duchenne muscular dystrophy and gene mutation site. Pediatr Neurol 2011;45:292–99 doi:10.1016/j.pediatrneurol.2011.08.003 pmid:22000308

   CrossRefPubMed
4. 4.↵
   1. Banihani R,
   2. Smile S,
   3. Yoon G, et al

   . Cognitive and neurobehavioral profile in boys with Duchenne muscular dystrophy. J Child Neurol 2015;30:1472–82 doi:10.1177/0883073815570154 pmid:25660133

   CrossRefPubMed
5. 5.↵
   1. Doorenweerd N,
   2. Dumas EM,
   3. Ghariq E, et al

   . Decreased cerebral perfusion in Duchenne muscular dystrophy patients. Neuromuscul Disord 2017;27:29–37 doi:10.1016/j.nmd.2016.10.005 pmid:27927595

   CrossRefPubMed
6. 6.↵
   1. Doorenweerd N,
   2. Straathof CS,
   3. Dumas EM, et al

   . Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy: quantitative MRI in DMD brain. Ann Neurol 2014;76:403–11 doi:10.1002/ana.24222 pmid:25043804

   CrossRefPubMed
7. 7.↵
   1. Fu Y,
   2. Dong Y,
   3. Zhang C, et al

   . Diffusion tensor imaging study in Duchenne muscular dystrophy. Ann Transl Med 2016;4:109 doi:10.21037/atm.2016.03.19] pmid:27127762

   CrossRefPubMed
8. 8.↵
   1. Muntoni F,
   2. Torelli S,
   3. Ferlini A

   . Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731–40 doi:10.1016/S1474-4422(03)00585-4 pmid:14636778

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Doorenweerd N,
   2. Mahfouz A,
   3. van Putten M, et al

   . Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci Rep 2017;7:12575 doi:10.1038/s41598-017-12981-5 pmid:28974727

   CrossRefPubMed
10. 10.↵
    1. Hinton VJ,
    2. De Vivo DC,
    3. Nereo NE, et al

    . Poor verbal working memory across intellectual level in boys with Duchenne dystrophy. Neurology 2000;54:2127–32 doi:10.1212/wnl.54.11.2127 pmid:10851376

    Abstract/FREE Full Text
11. 11.↵
    1. Taylor PJ,
    2. Betts GA,
    3. Maroulis S, et al

    . Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS One 2010;5:e8803 doi:10.1371/journal.pone.0008803 pmid:20098710

    CrossRefPubMed
12. 12.↵
    1. Tracey I,
    2. Scott RB,
    3. Thompson CH, et al

    . Brain abnormalities in Duchenne muscular dystrophy: phosphorus-31 magnetic resonance spectroscopy and neuropsychological study. Lancet 1995;345:1260–64 doi:10.1016/S0140-6736(95)90923-0 pmid:7746055

    CrossRefPubMed
13. 13.↵
    1. Lee JS,
    2. Pfund Z,
    3. Juhász C, et al

    . Altered regional brain glucose metabolism in Duchenne muscular dystrophy: a PET study. Muscle Nerve 2002;26:506–12 doi:10.1002/mus.10238 pmid:12362416

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Lv SY,
    2. Zou QH,
    3. Cui JL, et al

    . Decreased gray matter concentration and local synchronization of spontaneous activity in the motor cortex in Duchenne muscular dystrophy. AJNR Am J Neuroradiol 2011;32:2196–200 doi:10.3174/ajnr.A2718 pmid:21960496

    Abstract/FREE Full Text
15. 15.↵
    1. Miller SA,
    2. Dykes DD,
    3. Polesky HF

    . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215 doi:10.1093/nar/16.3.1215 pmid:3344216

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Oldfield RC

    . The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97–113 doi:10.1016/0028-3932(71)90067-4 pmid:5146491

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Walker LS,
    2. Greene JW

    . The functional disability inventory: measuring a neglected dimension of child health status. J Pediatr Psychol 1991;16:39–58 doi:10.1093/jpepsy/16.1.39 pmid:1826329

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Jones-Gotman M

    . Memory for designs: the hippocampal contribution. Neuropsychologia 1986;24:193–203 doi:10.1016/0028-3932(86)90052-7 pmid:3714024

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Smith SM,
    2. Nichols TE

    . Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83–98 doi:10.1016/j.neuroimage.2008.03.061 pmid:18501637

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Johansen-Berg H, et al

    . Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487–505 doi:10.1016/j.neuroimage.2006.02.024 pmid:16624579

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Cotton S,
    2. Voudouris NJ,
    3. Greenwood KM

    . Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol 2001;43:497–501 doi:10.1017/s0012162201000913 pmid:11463183

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Snow WM,
    2. Anderson JE,
    3. Jakobson LS

    . Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav Rev 2013;37:743–52 doi:10.1016/j.neubiorev.2013.03.016 pmid:23545331

    CrossRefPubMed
23. 23.↵
    1. Hinton VJ,
    2. Fee RJ,
    3. Goldstein EM, et al

    . Verbal and memory skills in males with Duchenne muscular dystrophy. Dev Med Child Neurol 2007;49:123–28 doi:10.1111/j.1469-8749.2007.00123.x pmid:17254000

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Kim TW,
    2. Wu K,
    3. Black IB

    . Deficiency of brain synaptic dystrophin in human Duchenne muscular dystrophy. Ann Neurol 1995;38:446–49 doi:10.1002/ana.410380315 pmid:7668831

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Ricotti V,
    2. Roberts RG,
    3. Muntoni F

    . Dystrophin and the brain. Dev Med Child Neurol 2011;53:12 doi:10.1111/j.1469-8749.2010.03836.x pmid:21171237

    CrossRefPubMed
26. 26.↵
    1. Dubowitz V,
    2. Crome L

    . The central nervous system in Duchenne muscular dystrophy. Brain J Brain 1969;92:805–08 doi:10.1093/brain/92.4.805 pmid:5364010

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Rosman NP,
    2. Kakulas BA

    . Mental deficiency associated with muscular dystrophy: a neuropathological study. Brain J Neurol 1966;89:769–88 doi:10.1093/brain/89.4.769 pmid:4163581

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Xu S,
    2. Shi D,
    3. Pratt SJP, et al

    . Abnormalities in brain structure and biochemistry associated with mdx mice measured by in vivo MRI and high resolution localized (1)H MRS. Neuromuscul Disord 2015;25:764–72 doi:10.1016/j.nmd.2015.07.003 pmid:26236031

    CrossRefPubMed
29. 29.↵
    1. Rae C,
    2. Scott RB,
    3. Thompson CH, et al

    . Brain biochemistry in Duchenne muscular dystrophy: a 1H magnetic resonance and neuropsychological study. J Neurol Sci 1998;160:148–57 doi:10.1016/S0022-510X(98)00190-7 pmid:9849797

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Kreis R,
    2. Wingeier K,
    3. Vermathen P, et al

    . Brain metabolite composition in relation to cognitive function and dystrophin mutations in boys with Duchenne muscular dystrophy. NMR Biomed 2011;24:253–62 doi:10.1002/nbm.1582 pmid:21404337

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Doorenweerd N,
    2. Hooijmans M,
    3. Schubert SA, et al

    . Proton magnetic resonance spectroscopy indicates preserved cerebral biochemical composition in Duchenne muscular dystrophy patients. J Neuromuscul Dis 2017;4:53–58 doi:10.3233/JND-160201 pmid:28269793

    CrossRefPubMed
32. 32.↵
    1. Acosta-Cabronero J,
    2. Williams GB,
    3. Pengas G, et al

    . Absolute diffusivities define the landscape of white matter degeneration in Alzheimer’s disease. Brain 2010;133:529–39 doi:10.1093/brain/awp257 pmid:19914928

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Beaulieu C

    . The basis of anisotropic water diffusion in the nervous system: a technical review. NMR Biomed 2002;15:435–55 doi:10.1002/nbm.782 pmid:12489094

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Aranmolate A,
    2. Tse N,
    3. Colognato H

    . Myelination is delayed during postnatal brain development in the mdx mouse model of Duchenne muscular dystrophy. BMC Neurosci 2017;18:63 doi:10.1186/s12868-017-0381-0 pmid:28806929

    CrossRefPubMed
35. 35.↵
    1. Goodnough CL,
    2. Gao Y,
    3. Li X, et al

    . Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo. Neuroimage 2014;102 Pt 2:809–16 doi:10.1016/j.neuroimage.2014.08.053 pmid:25213753

    CrossRefPubMed
36. 36.↵
    1. Nico B,
    2. Paola Nicchia G,
    3. Frigeri A, et al

    . Altered blood-brain barrier development in dystrophic MDX mice. Neuroscience 2004;125:921–35 doi:10.1016/j.neuroscience.2004.02.008 pmid:15120852

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Nico B,
    2. Roncali L,
    3. Mangieri D, et al

    . Blood-brain barrier alterations in MDX mouse: an animal model of the Duchenne muscular dystrophy. Curr Neurovasc Res 2005;2:47–54 doi:10.2174/1567202052773481 pmid:16181099

    CrossRefPubMed
38. 38.↵
    1. Nico B,
    2. Frigeri A,
    3. Nicchia GP, et al

    . Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia 2003;42:235–51 doi:10.1002/glia.10216 pmid:12673830

    CrossRefPubMedWeb of Science
39. 39.↵
    1. van der Werff SA,
    2. Andela CD,
    3. Nienke Pannekoek J, et al

    . Widespread reductions of white matter integrity in patients with long-term remission of Cushing’s disease. Neuroimage Clin 2014;4:659–67 doi:10.1016/j.nicl.2014.01.017 pmid:24936417

    CrossRefPubMed
40. 40.↵
    1. Pires P,
    2. Santos A,
    3. Vives-Gilabert Y, et al

    . White matter alterations in the brains of patients with active, remitted, and cured Cushing syndrome: a DTI study. AJNR Am J Neuroradiol 2015;36:1043–48 doi:10.3174/ajnr.A4322 pmid:25929879

    Abstract/FREE Full Text
41. 41.↵
    1. Sato Y,
    2. Yamauchi A,
    3. Urano M, et al

    . Corticosteroid therapy for Duchenne muscular dystrophy: improvement of psychomotor function. Pediatr Neurol 2014;50:31–37 doi:10.1016/j.pediatrneurol.2013.07.022 pmid:24138948

    CrossRefPubMed
42. 42.↵
    1. Tamma R,
    2. Annese T,
    3. Capogrosso RF, et al

    . Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice. Lab Invest 2013;93:592–610 doi:10.1038/labinvest.2013.46 pmid:23528847

    CrossRefPubMed